Tan YW, Chen L, Zhou XB. Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature. World J Clin Cases 2021; 9(17): 4415-4422 [PMID: 34141809 DOI: 10.12998/wjcc.v9.i17.4415]
Corresponding Author of This Article
You-Wen Tan, MD, Chief Doctor, Professor, Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, No. 300 Danjiamen, Runzhou District, Zhenjiang 212003, Jiangsu Province, China. tyw915@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 16, 2021; 9(17): 4415-4422 Published online Jun 16, 2021. doi: 10.12998/wjcc.v9.i17.4415
Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature
You-Wen Tan, Li Chen, Xing-Bei Zhou
You-Wen Tan, Li Chen, Xing-Bei Zhou, Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang 212003, Jiangsu Province, China
Author contributions: Tan YW and Chen L designed the research; Zhou XB collected and analyzed the data, and drafted the manuscript; Tan YW wrote and revised the manuscript; all authors have read and approved the final version to be published.
Informed consent statement: Informed consent was obtained from the patient.
Conflict-of-interest statement: All authors have no conflict of interest related to the manuscript.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: You-Wen Tan, MD, Chief Doctor, Professor, Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, No. 300 Danjiamen, Runzhou District, Zhenjiang 212003, Jiangsu Province, China. tyw915@sina.com
Received: February 4, 2021 Peer-review started: February 4, 2021 First decision: February 24, 2021 Revised: February 27, 2021 Accepted: March 25, 2021 Article in press: March 25, 2021 Published online: June 16, 2021 Processing time: 111 Days and 8.4 Hours
Core Tip
Core Tip: Immune checkpoint inhibitors can lead to immune-associated hepatitis and severe liver damage that can be life-threatening without specific treatment. Corticosteroids and immunosuppressants do not show sufficient sensitivity and their use often leads to serious complications such as severe secondary infections. Here we report a case of severe liver damage caused by death protein 1 inhibitors and the first use of dual-molecule plasma adsorption combined with plasma exchange to achieve satisfactory results. In addition, the clinical biochemical indicators in this case were sufficient for diagnosing acute liver failure, while pathology provided an accurate diagnosis. Pathological diagnosis is a very important diagnostic tool for severe liver injury.
